Microbiotix, Inc.
Microbiotix, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery and development of proprietary small molecule drugs targeting serious infectious diseases, including multi-drug resistant pathogens. The company is recognized for its innovation and has consistently been a top recipient of NIH awards among Massachusetts biotech/pharma companies.
Industries
Nr. of Employees
small (1-50)
Microbiotix, Inc.
One Innovation Drive, Worcester, MA 01605
Patents
Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
2022-11-22 • US-11505533-B2
View Details
Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
2022-11-22 • US-11505533-B2
View DetailsProducts
Oral nucleoside-analog antiviral candidate for CMV and ocular viruses (completed Phase 1)
A small-molecule nucleoside analog antiviral with dual DNA polymerase and kinase inhibitory activity, demonstrated in vitro potency, activity versus resistant isolates, no genotoxicity reported, and completion of Phase 1 clinical testing. Also evaluated for adenoviral conjunctivitis and other ocular viral indications in preclinical studies.
Spectinomycin-derivative antibacterial series for TB (spectinamides)
Semisynthetic spectinomycin analogs optimized for narrow-spectrum antitubercular activity with demonstrated in vitro potency, lack of cross-resistance to standard TB agents, and efficacy in multiple in vivo TB models.
Aminospectinomycins for drug-resistant gonorrhea and other pathogens
Novel spectinomycin-derived compounds with improved potency against Gram-negative and Gram-positive species, including activity versus drug-resistant Neisseria gonorrhoeae and efficacy in in vivo models.
Type III secretion system inhibitor program (Pseudomonas antivirulence)
Small-molecule inhibitors targeting the Type III secretion system of Pseudomonas aeruginosa to block toxin delivery, reverse disruption of host innate immunity, and reduce establishment and dissemination of infection.
Pyranopyridine efflux pump inhibitor program (RND pumps)
Development of pyranopyridine-derived inhibitors of RND-type efflux pumps intended for use as adjunctive therapy to increase antibiotic potency and reduce resistance frequency in Enterobacteriaceae and other Gram-negative pathogens.
Oral nucleoside-analog antiviral candidate for CMV and ocular viruses (completed Phase 1)
A small-molecule nucleoside analog antiviral with dual DNA polymerase and kinase inhibitory activity, demonstrated in vitro potency, activity versus resistant isolates, no genotoxicity reported, and completion of Phase 1 clinical testing. Also evaluated for adenoviral conjunctivitis and other ocular viral indications in preclinical studies.
Spectinomycin-derivative antibacterial series for TB (spectinamides)
Semisynthetic spectinomycin analogs optimized for narrow-spectrum antitubercular activity with demonstrated in vitro potency, lack of cross-resistance to standard TB agents, and efficacy in multiple in vivo TB models.
Aminospectinomycins for drug-resistant gonorrhea and other pathogens
Novel spectinomycin-derived compounds with improved potency against Gram-negative and Gram-positive species, including activity versus drug-resistant Neisseria gonorrhoeae and efficacy in in vivo models.
Type III secretion system inhibitor program (Pseudomonas antivirulence)
Small-molecule inhibitors targeting the Type III secretion system of Pseudomonas aeruginosa to block toxin delivery, reverse disruption of host innate immunity, and reduce establishment and dissemination of infection.
Pyranopyridine efflux pump inhibitor program (RND pumps)
Development of pyranopyridine-derived inhibitors of RND-type efflux pumps intended for use as adjunctive therapy to increase antibiotic potency and reduce resistance frequency in Enterobacteriaceae and other Gram-negative pathogens.
Expertise Areas
- Antiviral therapeutics development
- Antibiotic discovery for multidrug-resistant pathogens
- Preclinical pharmacology and in vivo infection models
- Medicinal chemistry and SAR
Key Technologies
- Small-molecule medicinal chemistry
- Nucleoside-analog antiviral chemistry
- In vitro virology assays
- In vitro antibacterial assays (including efflux and trans-translation assays)
Key People
President & CEO
Chief Business Officer
President & CEO
Chief Business Officer
News & Updates
Microbiotix has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies.
Microbiotix has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies.